Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Stockholders' Equity (Unaudited)

v3.8.0.1
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Paid-in Capital
Accumulated Other Comprehensive Income (loss)
Retained Deficit
Beginning Balance (in shares) at Dec. 31, 2016   158,829,816      
Beginning Balance at Dec. 31, 2016 $ 2,183,892 $ 1,588 $ 3,946,442 $ (53,058) $ (1,711,080)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 154,455       154,455
Other Comprehensive Income 1,373     1,373  
Stock-based Compensation 2,553   2,553    
Issuance of Common Stock for the Vitruvian Acquisition, net of related expenses (in shares)   23,852,117      
Issuance of Common Stock for the Vitruvian Acquisition, net of related expenses 459,481 $ 239 459,242    
Issuance of Restricted Stock (in shares)   153,868      
Issuance of Restricted Stock 0 $ 1 (1)    
Ending Balance (in shares) at Mar. 31, 2017   182,835,801      
Ending Balance at Mar. 31, 2017 $ 2,801,754 $ 1,828 4,408,236 (51,685) (1,556,625)
Beginning Balance (in shares) at Dec. 31, 2017 183,105,910 183,105,910      
Beginning Balance at Dec. 31, 2017 $ 3,101,614 $ 1,831 4,416,250 (40,539) (1,275,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 90,090       90,090
Other Comprehensive Income (5,503)     (5,503)  
Stock-based Compensation 2,685   2,685    
Shares Repurchased (in shares)   (9,692,356)      
Shares Repurchased (99,997) $ (97) (99,900)    
Issuance of Restricted Stock (in shares)   109,933      
Issuance of Restricted Stock $ 0 $ 1 (1)    
Ending Balance (in shares) at Mar. 31, 2018 173,523,487 173,523,487      
Ending Balance at Mar. 31, 2018 $ 3,088,889 $ 1,735 $ 4,319,034 $ (46,042) $ (1,185,838)